eFFECTOR Therapeutics, Inc. (EFTR) News
Filter EFTR News Items
EFTR News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
EFTR News Highlights
- EFTR's 30 day story count now stands at 2.
- Over the past 10 days, the trend for EFTR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- MG, DEC and NOV are the most mentioned tickers in articles about EFTR.
Latest EFTR News From Around the Web
Below are the latest news stories about EFFECTOR THERAPEUTICS INC that investors may wish to consider to help them evaluate EFTR as an investment opportunity.
eFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer PatientsMedian progression free survival (mPFS) of 7.4 months in the ZFA expansion cohort evaluating zotatifin in combination with fulvestrant and abemaciclib in heavily pretreated patients Zotatifin generally well tolerated as dose escalation continues; Currently enrolling at 0.28 mg/kg in the ZF doublet evaluating zotatifin combined with fulvestrant and at 0.1 mg/kg in the ZFA triplet SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Dec. 08, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: |
eFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast CancerDesignation is for 2nd or 3rd line treatment of patients with disease progression following treatment with endocrine therapy and a CDK 4/6 inhibitor Data updates and further development plans to be presented at 2023 San Antonio Breast Cancer Symposium (SABCS) SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, toda |
eFFECTOR to Present New Clinical Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Patients with ER+ Metastatic Breast Cancer at SABCS 2023 Annual MeetingSOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced a poster presentation of new clinical data from dose escalation and Phase 2 expansion cohorts of a Phase 1/2 clinical study of zotatifin in patients with estrogen receptor positive (ER+) metastatic breast cancer (mBC) at the San Antonio Breast Canc |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayPre-market stock movers are worth checking out on Monday as we cover all of the biggest gainers and losers this morning! |
eFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateManagement intends to provide an update on its zotatifin clinical development program in estrogen receptor-positive (ER+) metastatic breast cancer (mBC) at the 2023 San Antonio Breast Cancer Symposium (SABCS) Topline results from Phase 2b KICKSTART trial in non-small cell lung cancer (NSCLC) now anticipated in first quarter of 2024 Collaboration initiated with Northwestern University on investigator-initiated Phase 1 dose escalation trial with tomivosertib in patients with Acute Myeloid Leukemia |
eFFECTOR Therapeutics to Participate in Fireside Chat at 2023 Stifel Healthcare ConferenceSOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that the Company will participate in a fireside chat discussion and host 1x1 meetings at the 2023 Stifel Healthcare Conference taking place November 14-15, 2023 in New York, NY. Steve Worland, Ph.D., president and chief executive officer of eFFEC |
eFFECTOR Therapeutics to Collaborate with the Northwestern University Division of Hematology and Oncology on an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Acute Myeloid LeukemiaTrial designed to capitalize on previously published results that showed preclinical activity of tomivosertib in AML modelsSOLANA BEACH, Calif. and REDWOOD CITY, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced the initiation of dosing in an investigator-initiated Phase 1 dose escalation trial evaluating tomivosertib in patients with |
3 Promising Biotech Stocks That Will Make Early Investors RichDespite their volatility, certain biotech stocks stand out for their innovative approaches and potential game-changing therapies. |
eFFECTOR Therapeutics to Participate in Upcoming Investor ConferencesSOLANA BEACH, Calif. and REDWOOD CITY, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that the management team will participate in and host 1x1 meetings at the following upcoming investor conferences: Presentation at the H.C. Wainwright 25th Annual Global Investment Conference on September 13 at 10AM ETFireside chat at the 2023 Ca |
eFFECTOR Therapeutics First Half 2023 Earnings: US$0.41 loss per share (vs US$0.093 loss in 1H 2022)eFFECTOR Therapeutics ( NASDAQ:EFTR ) First Half 2023 Results Key Financial Results Net loss: US$18.4m (loss widened by... |